Company overview
NervGen Pharma is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics, including lead candidate NVG-291, a subcutaneously administered peptide targeting spinal cord injury in Phase 1b/2a trials. NVG-291 promotes nervous system repair by countering chondroitin sulfate proteoglycans (CSPGs) to enable axonal regeneration, neuroplasticity, and remyelination. The company is also advancing NVG-300 in preclinical models for neurotraumatic and neurologic conditions, supported by U.S. Department of Defense funding.
Nervgen is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include nervgen pharma, nvg-291, spinal cord injury, neuroreparative therapeutics, cspg peptide.
Structured facts
- Website
- https://nervgen.com/
- Markets served
- United States & Americas
- Keywords
- nervgen pharma, nvg-291, spinal cord injury, neuroreparative therapeutics, cspg peptide
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What is NervGen's lead product candidate and its development stage?
- NVG-291 is a first-in-class neuroreparative peptide in Phase 1b/2a clinical trials (CONNECT SCI Study) for chronic spinal cord injury, demonstrating improved function and quality of life.
- What therapeutic areas does NervGen target?
- Primary focus is spinal cord injury, with preclinical work on traumatic brain injury, traumatic hearing loss, ischemic stroke, and potential in multiple sclerosis via NVG-291 and NVG-300.
- What is the mechanism of action for NVG-291?
- NVG-291 relieves inhibitory effects of CSPGs to promote axonal regeneration, neuroplasticity, remyelination, and functional recovery such as locomotion and bladder control in preclinical models.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
